Connect with us
  • ciitech

News

Microdosing THC lessens chronic pain – study

Published

on

Microdoses of THC can deliver pain reduction without the high associated with the psychoactive element of cannabis, according to an Israeli study.

Israeli med-tech company Syqe Medical has conducted the first clinical trial to demonstrate that extremely low and precise doses of inhaled THC – the principal psychoactive constituent of cannabis – can effectively relieve pain, while avoiding the common side effects associated with cannabis use.

The study, published in the European Journal of Pain, is the first scientific confirmation that microdosing – the process of using extremely low doses of active drug compounds to treat various conditions – actually works with cannabis.

Although widely championed, until now there has been scarce scientific evidence to support or even fully explore claims of microdosing benefits and safety.

The placebo-controlled, double-blind, multi-dose study was conducted at Rambam Medical Center in Israel and examined blood THC levels, pain relief, cognitive functions and psychoactivity.

The study shows that an optimally effective dose to relieve pain is just 500 micrograms of THC.

Syqe patients consume d3-4 inhalations per day, each up to 500 micrograms. A typical medical cannabis patient consumes 1 gram of 15 per cent THC cannabis per day, which contains 150,000 micrograms of THC.

This illustrates a key finding from the study that patients can benefit from dramatically lower doses.

The Syqe Selective-Dose Inhaler, the company’s novel drug delivery platform marketed in Israel by pharmaceutical giant Teva, allows physicians and patients to select microgram-level doses with unprecedented precision.

Syqe believes that the published study and the actual patient use data in Israel will be an important part of its planned FDA submission in the U.S.

Perry Davidson, Syqe Medical CEO, said: “This study is the first to show that human sensitivity to THC is significantly greater than previously assumed, indicating that if we can treat patients with much higher precision, lower quantities of drug will be needed, resulting in fewer side effects and an overall more effective treatment.

“The Syqe drug delivery technology is also applicable to opioids and other compounds that, while potentially effective, are notoriously associated with dangerous side effects.

“The introduction of a tool to prescribe medications at such low doses with such high resolution may allow us to achieve treatment outcomes that previously were not possible.”

These findings may allow the establishment of a long-awaited industry milestone: a standardised therapeutic window for cannabis inhalation.

Proffessor Elon Eisenberg, lead researcher and dean of the Faculty of Medicine at the Technion-Israel Institute of Technology, said: “We can conclude from the study results that low doses of cannabis may provide desirable effects while avoiding cognitive debilitations, significantly contributing to daily functioning, quality of life, and safety of the patient.

“The doses given in this study, being so low, mandate very high precision in the treatment modality. This precision is unique to the Syqe drug delivery technology, enabling cannabis dosing at pharmaceutical standards.”

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

News

Beckham-backed cannabis brand floats on LSE

Published

on

Cannabis firms MGC Pharma and Kanabo became the first two companies to list on the LSE

A UK cannabis company, backed by David Beckham, has been valued in excess of £25 million in its first day trading on the London stock market.

UK-based Cellular Goods has become the first provider of consumer products based on biosynthetic cannabinoids to join the London stock market.

The company has been admitted to the Official List following a significantly oversubscribed initial public offering that raised £13 million before expenses.

More than 6,000 valid applications for shares were received in respect of the IPO. 

Shares will commence trading on the main market of the LSE from 8am on Friday 26 February, under the ticker symbol CBX. 

A total of 260,000,000 ordinary shares have been issued at five pence each to institutional and retail investors, valuing Cellular Goods at a market capitalisation in excess of £25 million.

Cellular Goods was established in August 2018 to develop efficacy-led and research-backed cannabinoid products. 

The initial focus is on premium skincare and topical athletic recovery products to be launched from this autumn. 

Earlier this month it was revealed that former England footballer, David Beckham’s investment firm, DB Ventures had bought a stake in the company.

The firm follows European based MGC Pharma and Israeli firm Kanabo which made history as the first and second companies to list on the LSE this month.

The purpose of the flotation on the LSE is to raise the public profile and provide new funds for the company’s expansion and long-term growth. 

“Cellular  Goods’ debut on the London Stock Exchange is a major step in the company’s development and provides a strong foundation to execute our long-term growth strategy,”commented Alexis Abraham, chief executive officer

“We are delighted with the strong support from a wide range of institutional and retail investors to build premium consumer products based on biosynthetic cannabinoids under the Cellular Goods brand.” 

Continue Reading

News

First study of cannabis in veterans with PTSD

Published

on

Up to half a million US army veterans have been diagnosed with PTSD in the last 13 years

The first observational study to determine the efficacy of cannabis for veterans with PTSD has gained approval from regulators in the US.

US charity, The Battle Brothers Foundation has received approval to launch an observational study on the use of medical cannabis to help combat PTSD in veterans. 

In conjunction with NiaMedic, a medical data and research company, the study will determine if cannabis treatment will be beneficial in reducing symptoms in patients with treatment-resistant PTSD

The two groups received approval to proceed with the study from the national Independent Review Board (IRB), the independent committee that reviews the methods proposed for research to ensure that they are ethical.

“This news could not come at a better time,” Bryan Buckley, founder and president of the board for Battle Brothers Foundation.

“Every day, 22 veterans are dying due to effects of post-traumatic stress from opioid addiction to depression. Through anecdotal experiences, we know that cannabis can alleviate symptoms and provide relief. 

“We appreciate that the IRB recognises the validity of and the need for this study.”

According to the National Institutes of Health, the rate of PTSD among returning service members varies widely across wars and eras. 

In one major study of 60,000 Iraq and Afghanistan veterans, 13.5 percent of deployed and non-deployed veterans screened positive for PTSD, while other studies show the rate to be as high as 20 to 30 percent. 

As many as 500,000 US troops who served in these wars over the past 13 years have been diagnosed with PTSD.

The study will enroll 60 California veterans, with moderate or severe PTSD over the next year.

Participants will dose and titrate individually purchased products under their own discretion and will be followed for 90 days to evaluate the safety and efficiency of cannabis on their symptoms. 

Results of the study will be documented and monitored at that time.

The Battle Brothers Foundation is the nonprofit arm of Helmand Valley Growers Company (HVGC), a cannabis company founded by disabled United States Special Operations veterans that donates 100 percent of its profits to fund research on the medical use of cannabis for veterans.

Continue Reading

News

Can CBD improve your fitness?

Published

on

Utilising CBD can help boost your fitness routine

The market is full of products which promise weight loss, muscle gain and recovery benefits, with glowing endorsements from all kinds of sportspeople. Here we explore what CBD has to offer.

From reducing risks of conditions such as heart disease to improving overall mood, getting the right amount and right kind of exercise provides numerous benefits for both physical and mental health.

With the likes of gyms, leisure centres and exercise classes closed due to the Covid-19 pandemic, many of us have resorted to home workouts for the first time and are looking for the perfect supplement to aid these sessions – could CBD be the one?

 

One of the most popular reasons for using CBD as part of your exercise routine is the effect it has on recovery and pain relief. Whether you’re suffering from a slight niggle or a long-term injury, the remedy has been proven to speed recovery and fight fatigue, with one study finding that by reducing oxidative damage – which is caused by physical stress – CBD can help us recover faster and perform better.

Topical CBD products such as creams can be particularly beneficial to those who are prone to joint pain, by providing highly targeted relief to ensure that those unavoidable twinges don’t negatively impact your overall workout.  

In addition, CBD may also be effective in relieving muscular aches and soreness thanks to its anti-inflammatory properties. A 2009 study into the effects of cannabinoids on the body found that they can suppress inflammatory response, leading to less tension in the area and, in turn, less of a break needed between your workouts. 

One of the biggest pre-workout struggles is building enough motivation and momentum to get started and keep your routine going. While it hasn’t been shown to be a performance-enhancing product, the research into CBD’s effect on areas such as mental health and sleep quality leads us to believe that it can be a great supplement for breaking down mental barriers.

Several studies have linked CBD to overall improvement in mood, while it has also been well documented that the remedy can effectively ease symptoms of depression thanks to its positive effect on serotonin receptors in the brain. While CBD doesn’t necessarily boost these levels, its impact on the brain’s receptors may affect how we respond to the serotonin already in our systems.

Research backs up these claims, with a 2014 animal study finding that CBD’s effect on the receptors produced both antidepressant and anti-anxiety effects – both of which can be extremely helpful when gathering motivation to exercise. 

Too tired for a workout? A review of studies in 2017 found that CBD “may have therapeutic potential for the treatment of insomnia”, meaning it’s likely to improve sleep quality, allowing us to wake up feeling refreshed and ready to take on a workout. 

While research into certain areas is still ongoing, and it’s worth noting that effects will depend on external factors such as dosage, it would appear that CBD has several pre- and post-workout benefits.

Continue Reading

Trending